Tuesday, August 31, 2021

Natural Immunity vs. Vaccine Immunity to the SARS-CoV-2 Virus - Which is Superior

A recent study from Israel, the "canary in the coal mine" when it comes to COVID-19 vaccination programs compares natural immunity to the SARS-CoV-2 virus to that achieved through vaccination.  Let's look at the results of the study by Dr. Sivan Gazit et al entitled "Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections" as shown here:


Please note that the research has not been peer reviewed at this time.

 

The authors conducted a retrospective observational study comparing three groups of individuals noting that the fully vaccinated group served as the reference group for the study.:

 

1.) Individuals who had not been infected by the SARS-CoV-2 virus previously (SARS-CoV-2-naive) and who received a two-dose regimen of the Pfizer - BioNTech mRNA vaccine by February 28, 2021 and who did not receive the third dose of vaccine by the end of the study period.  A total of 673,676 individuals met this requirement.

 

2.) individuals who had been previously infected by the SARS-CoV-2 virus as recorded using a PCR test by February 28, 2021 and had not been vaccinated.  A total of 62,883 individuals met this requirement.

 

3.) individuals who had been previously infected with the SARS-CoV-2 virus by February 28, 2021 and who had receive a single dose of vaccine by May 25, 2021.  A total of 42,099 individuals met this requirement.

  

This is the largest real-world observational study that has been undertaken to date which compares natural immunity gained through previous SARS-CoV-2 infections to those afforded by Pfizer's BNT162b2 mRNA vaccine.

 

The study population included individuals aged 16 years and older who were vaccinated prior to February 28, 2021, who had a documented SARS-CoV-2 infection by February 28, 2021 or who had both a documented SARS-CoV-2 infection by February 28, 2021 and received one dose of the vaccine by May 25, 2021, 7 days prior to the study period began.

 

The authors evaluated four outcomes:

 

1.) SARS-CoV-2 infection.

 

2.) symptomatic disease.

 

3.) COVID-19-related hospitalization.

 

4.) COVID-19-related death.

 

The follow-up period was from June 1, 2021 to August 14, 2021 when the Delta variant was predominant in Israel.  

 

Here are the results of two of the models used, noting that the authors adjusted the results for comorbidities:

 

1.) Model 1 - Previously infected vs. vaccinated individuals with matching for the time of the first event:

 

During the followup period, a total of 257 cases of SARS-CoV-2 infection were recorded with 238 occurring in the vaccinated group (breakthrough infections), 19 in the previously infected group (reinfections).  SARS-CoV-2-naive vaccinated individuals were 13.06 times more likely to have a breakthrough infection with the Delta variant compared to those who were previously infected with the virus.  

 

As for symptomatic infections during the followup period, a total of 199 cases were recorded, 191 of which were in the vaccinated group and 8 in the previously infected group.  SARS-CoV-2-naive vaccinated individuals were 27.02 times more likely to have a symptomatic breakthrough infection with the Delta variant compared to those who were previously infected with the virus.

 

As for hospitalizations, a total of 9 COVID-19 hospitalizations were recorded, 8 of which were in the vaccinated group and 1 in the previously infected group.

 

No COVID-19-related deaths were recorded.

 

2.) Model 2 - Previously infected vs. vaccinated individuals without matching for the time of the first event:

 

When comparing fully vaccinated individuals to those previously infected (including during 2020), the authors found that throughout the followup period there were 748 cases of SARS-CoV-2 infection, 640 of which were in the vaccinated group (breakthrough infections) and 108 in the previouslyinfected group (reinfections).  SARS-CoV-2-naive vaccinated individuals were 5.96 times more likely to have a breakthrough infection with the Delta variant compared to those that were previously infected with the virus.

 

As for symptomatic infections, a total of 522 cases were recorded, 484 of which were in the vaccinated group and 68 in the previously infected group.  SARS-CoV-2-naive vaccinated individuals were 7.13 times more likely to have a symptomatic breakthrough infection with the Delta variant compared to those who were previously infected with the virus.

 

As for hospitalizations, a total of 25 COVID-19 hospitalizations were recorded, 21 of which were in the vaccinated group and 4 in the previously infected group.  Vaccinated individuals were 6.7 times more likely to be admitted to hospital than those who were reinfected.

 

No COVID-19-related deaths were recorded.

 

Here is an excerpt from the paper's conclusion:

 

"This analysis demonstrated that natural immunity affords longer lasting and stronger protection against infection, symptomatic disease and hospitalization due to the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Notably, individuals who were previously infected with SARS-CoV-2 and given a single dose of the BNT162b2 vaccine gained additional protection against the Delta variant. The long-term protection provided by a third dose, recently administered in Israel, is still unknown."


4 comments:

  1. Dang! This certainly puts all the ducks in a row. I've had my suspicions but this important work lays it all out for me. I think I had covid in November 2019. I don't know a single soul whose had covid but I've had two friends die the day after the vax. One announced on social media he'd just received his second shot and "Look out world, here I come" and was dead in 12 hours. Almost eerie. Regardless of what the new reich wants. I ain't taking their bug juice. Great post. Sorry about google harassing you. I'm working on "Instant Pharmas gonna get you" music.

    ReplyDelete
  2. Yes, that paper is worth consideration and discussion. But there is a risk though for tribal interpretation and out-of-context generalization.
    As usual, this needs to be replicated and numbers (outcomes) are relatively small. Also, the study is retrospective and based on voluntary testing, which is a potential source of data bias. The biggest issues are that 1-the conclusions are, at this time, specific for the quite unusual situation Israel finds itself in (very very high vaccination coverage, especially for the at-risk groups) and 2-the two groups (vaccinated and unvaccinated are wildly different). The vaccinated group contains older and at-risk groups while the unvaccinated group contains mostly young and healthy groups. It is like comparing apples to oranges. Also, Simpson's paradox applies and fails to reveal what happens in relevant subgroups.
    For reference, look at the following:
    https://www.haaretz.com/israel-news/israel-covid-graphs-prove-vaccines-works-delta-pfizer-1.10101640
    https://www.covid-datascience.com/post/israeli-data-how-can-efficacy-vs-severe-disease-be-strong-when-60-of-hospitalized-are-vaccinated
    In Israel, at this point, their “78%” two-doses vaccination coverage is really more like 60% if you include total population and almost 25% of their population is 12 years and younger (it’s being reported that children aged 0-3 get and transmit the virus (especially the Delta variant) quite significantly). In Israel, despite the recent report, the vaccines continue, convincingly and up to now, to work extremely well and safely to protect against Covid severe disease in older and other at-risk groups.
    Natural immunity is important but exclusive reliance on this aspect with effective vaccines available means continued spread in the unvaccinated and, eventually, spread, re-infection and “breakthrough” cases in vulnerable (even if already vaccinated) populations. Eventually, that scenario will play out similarly in the US (with an associated very high and preventable covid disease burden in the interim in both the unvaccinated and vaccinated groups). For this specific aspect, some areas are ahead of the curve (like San Francisco), some are doing relatively well and some other states continue to be natural laboratories for the formation of more variants and a somewhat elevated covid disease burden (ie Alabama, Missouri, Florida, Texas etc). Some states have even been able to report quite high numbers of children hospitalizations (yeah i know not a population extinction event but still…).
    By the time the US reaches the vicinity of herd immunity, an unusual amount of emphasis will have been put on individual and ‘natural’ defense and not enough emphasis on what humans can accomplish together.
    It’s OK to not accept vaccines for whatever reason but it’s also important to realize that peer-reviewed and extremely good quality evidence shows that each incremental percentage of people not taking vaccines means a quasi-exponential rise (that’s what a virus with a high R0 does; delta’s R0 at around 6.5) in disease burden at the bipolar population level.
    With all due respect, it's not surprising that your blog has become part of a watchlist for mis- or dis-information about Covid and the blog continues to report on already framed conclusions looking for evidence without evidence of an adequate analysis of underlying submitted data.

    ReplyDelete
  3. This summary does not seem to account for the difference in sizes of the groups with the vax group being 10x as large as the covid recovery group. Maybe the original paper did but the ratios given suggest not. So conclusions are incorrect, or maybe the summary is by a journalist who did not understand the nuances....

    ReplyDelete
  4. From the paper it appears the universe of patients was 10x but comparisons were of a subset of ~16,300
    from each group suggesting ratios were probably valid depending on morbidities, matching of which may be the reason for smaller subsets. So I withdraw my objections in the first post.

    ReplyDelete